Adverum Biotechnologies Inc
NASDAQ:ADVM
| Market Cap (Intraday) | 292.84M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.64 |
| 50-Day MA | $5.21 |
| 200-Day MA | $10.34 |
Adverum Biotechnologies Inc Stock, NASDAQ:ADVM
800 Saginaw Drive, Suite A, Redwood City, California 94063
United States of America
Phone: +1.650.656.9323
Number of Employees: 167
Description
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.